Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Protean Biodiagnostics - aVenture Company Research

Protean Biodiagnostics

Protean Biodiagnostics

Protean BioDiagnostics offers comprehensive CAP CLIA lab services and innovative cancer diagnostic solutions, focusing on community oncology and underserved populations.

Orlando, FL, US🇺🇸

Founded

Protean BioDiagnostics, founded with a mission to assist cancer patients and their doctors in navigating advanced diagnostic options, offers comprehensive CAP CLIA laboratory services. The company focuses on community oncology and underserved populations, providing innovative products based on molecular analysis, genomics, bioinformatics, digital pathology, and AI. Their market focus is primarily on enhancing cancer diagnostics to ensure patients receive the most effective therapies available.

Notable figures affiliated with Protean BioDiagnostics include key researchers and industry experts in oncology diagnostics. The company has achieved significant milestones, such as the launch of Aventa FusionPlus, the first 3D genomics test for cancer patients, in collaboration with Aventa. Protean's impact lies in its commitment to improving cancer diagnosis and treatment options, particularly for underserved communities, thereby advancing the field of oncology diagnostics.

Protean Biodiagnostics - Similar Companies

NeoGenomics Laboratories

neogenomics.com

Complete Omics

completeomics.com

Neodiagnostix

neodiagnostix.com

Protean Biodiagnostics - Quick Facts

Who are Protean Biodiagnostics' competitors?

Companies similar to Protean Biodiagnostics include NeoGenomics Laboratories, Complete Omics, Neodiagnostix and Predictive Biosciences.

When was Protean Biodiagnostics founded?

Protean Biodiagnostics was founded in 2017.

Where is Protean Biodiagnostics' headquarters located?

Protean Biodiagnostics' headquarters is located in Orlando, FL, US.

When was Protean Biodiagnostics' last funding round?

Protean Biodiagnostics' most recent funding round was for $330k (USD) in June 2019.

Protean Biodiagnostics - Classification

Industry: Professional Service Companies
Ownership: Private
Technology: AI
Genomics

How much disclosed funding has Protean Biodiagnostics raised?

As of Jun 26, 2019, Protean Biodiagnostics has disclosed funding of $330k (USD). Undisclosed round amounts are excluded.

How many employees does Protean Biodiagnostics have?

Protean Biodiagnostics has 14 employees as of Feb 5, 2024.

Geographic Exposure

United States

Revenue: Recurring
Customer: Enterprise
Main Product: Cancer Diagnostics
Lab Services

Tags: Biotech
Healthtech

NAICS: 540000Professional, Scientific, and Technical Services
541500Computer Systems Design and Related Services
541000Professional, Scientific, and Technical Services
541510Computer Systems Design and Related Services
541511Custom Computer Programming Services
SIC: 7300Business Services
7370Computer Programming, Data Processing, And Other Computer Related
7371Computer Programming Services

Show 15 more industry codes

NAICS: 513200Software Publishers
541714Research and Development in Biotechnology (except Nanobiotechnology)
510000Information
620000Health Care and Social Assistance
513000Publishing Industries
541700Scientific Research and Development Services
513210Software Publishers
541710Research and Development in the Physical, Engineering, and Life Sciences

Predictive Biosciences

EcoGenome

ecogenomellc.com

Avant Diagnostics

Salish Bioscience

Applied Proteomics

Circulogene Theranostics

circulogene.com

Capio Biosciences

Veracyte

veracyte.com

Proteogenix

Cadex Genomics

cadexgenomics.com

Accelerated Medical Diagnostics

PetDx

SIC

8000Health Services
8700Engineering, Accounting, Research, Management, And Related Services
8040Offices And Clinics Of Other Health Practitioners
8730Research, Development, And Testing Services
7372Prepackaged Software
8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
8731Commercial Physical and Biological Research